Agilent Technologies to Collaborate with National University of Singapore on Bioanalytical Studies
April 23 2015 - 11:00AM
Business Wire
Company to Support NUS Medicine’s Research
for Safer, More Effective Medicine for Heart Disease
Agilent Technologies Inc. (NYSE:A) today announced a strategic
collaboration with the National University of Singapore (NUS) Yong
Loo Lin School of Medicine in a move aimed to help researchers
develop more effective medicine to treat cardiovascular
disease.
The Department of Medicine at the Yong Loo Lin School of
Medicine at NUS will have access to the latest bioanalytical
instruments from Agilent as part of its in-depth study of clinical
bioanalytics—the body’s response to drug exposure.
“We are happy to be working with Agilent,” said assistant
professor Chester Drum, Department of Medicine at the NUS Yong Loo
Lin School of Medicine. “Agilent’s broad range of technologies
will, ultimately, aid in the development of new analytics for
personalized patient care. Consideration of the patient as an
individual, rather than a statistic, is where we will see the next
innovations in cardiovascular medicine.”
Dr. Drum, who is also with the Cardiovascular Research Institute
(CVRI) at the National University Heart Centre, Singapore, aims to
provide real-time readouts for patients to understand the
risk-benefit of commonly prescribed medications throughout the
lifecycle of a drug. Presently, the research is on drugs for heart
disease but could be extended to a host of related diseases, such
as high cholesterol, diabetes, etc. According to the World Health
Organization, cardiovascular disease was the No. 1 cause of death
worldwide in 2012(1).
“This collaboration with NUS Medicine is exciting, as we can see
that the potential outcomes could save lives or improve people’s
quality of life,” said Agilent’s Robin Philp, specialist for the
academic market in the South East Asia Pacific and Korea region.
“We appreciate the opportunity to collaborate with research leaders
like NUS Medicine, who will be using our technology to conduct
faster, more accurate research in their quest to answer science’s
tough questions.”
“As a leading cardiovascular research organization in Singapore,
we are delighted to partner with Agilent to enable the development
of cutting-edge analytical biochemistry infrastructure,
intellectual property and human capital in Singapore,” said
professor Mark Richards, director of the CVRI. “This partnership is
an excellent example of an intelligent extension of our institute’s
technical capacity while keeping in step with the needs of industry
for mutually constructive and productive partnerships with academic
biomedical research groups.”
Under the terms of the memorandum of understanding, Agilent will
provide access to its proof-of-concept laboratory in Singapore. One
of the instruments in the lab will be the Agilent 6550 iFunnel
quadrupole time-of-flight liquid chromatography mass spectrometry
(Q-TOF LC/MS) system. The 6550 is best suited for highly
challenging qualitative and quantitative analyses in applications
such as metabolomics, early-stage drug metabolism and
pharmacokinetics.
Dr. Drum’s team will also have access to the Agilent Capillary
Electrophoresis System model 7100, a high-sensitivity instrument
used for small sample amounts of charged substances such as
biomolecules, low molecular weight basic and acidic drugs and ions.
Both NUS Medicine and Agilent will have opportunities to present at
various industry or Agilent-led events or seminars in Asia Pacific
region.
About the NUS Yong Loo Lin School of Medicine
Established in 1905, the NUS Yong Loo Lin School of Medicine was
the first institution of higher learning in Singapore and the
genesis of what would become the National University of Singapore,
a leading global university centred in Asia. The School offers one
of the finest undergraduate medical programs in the Asia Pacific
region and commands international recognition and respect.
The latest university rankings from Quacqarelli Symonds (QS)
have again rated the School as one of Asia’s best. Globally, it is
now ranked 21.
The School admits 300 students to its medical undergraduate
degree programme annually. The School strives to fulfil its
tripartite mission of providing excellent clinical care, training
the next generation of healthcare professionals, and fostering
research that will transform the practice of medicine. It plays a
pivotal role in producing future leaders in healthcare delivery,
discovery and public service as well as in Singapore’s Biomedical
Sciences Initiative and Singapore Medicine, a medical tourism
initiative.
The School’s 16 departments in the basic sciences and clinical
specialties work closely with the Alice Lee Centre for Nursing
Studies and the Centre for Biomedical Ethics to ensure that
teaching and research are aligned and relevant to Singapore’s
healthcare needs.
For more information about the Yong Loo Lin School of Medicine,
please visit http://medicine.nus.edu.sg/corporate/.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A), a global leader in
life sciences, diagnostics and applied chemical markets, is the
premier laboratory partner for a better world. Agilent works with
customers in more than 100 countries, providing instruments,
software, services and consumables for the entire laboratory
workflow. Agilent generated revenues of $4.0 billion in fiscal
2014. The company employs about 12,000 people worldwide.
Information about Agilent is available at www.agilent.com.
(1)
http://www.who.int/mediacentre/factsheets/fs310/en/index2.html:
According to WHO, cardiovascular disease killed 17.5 million people
in 2012, or three in every 10 deaths.
NOTE TO EDITORS: Further technology, corporate citizenship and
executive news is available at www.agilent.com/go/news.
Agilent Technologies Inc.Victoria Wadsworth-Hansen, +45 2933
6980victoria.wadsworth-hansen@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2023 to Apr 2024